Document:

Exhibit
4.1

 

THIS
UNSECURED CONVERTIBLE PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (“ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED OR SOLD UNLESS
REGISTERED AND QUALIFIED PURSUANT TO THE APPLICABLE PROVISIONS OF FEDERAL AND STATE SECURITIES LAWS OR UNLESS AN EXEMPTION FROM SUCH
REGISTRATION AND QUALIFICATION APPLIES. THEREFORE, NO SALE OR TRANSFER OF THIS NOTE SHALL BE MADE, NO ATTEMPTED SALE OR TRANSFER SHALL
BE VALID, AND THE ISSUER SHALL NOT BE REQUIRED TO GIVE ANY EFFECT TO ANY SUCH TRANSACTION UNLESS (A) SUCH TRANSACTION HAS BEEN DULY REGISTERED
UNDER THE ACT AND QUALIFIED OR APPROVED UNDER APPROPRIATE STATE SECURITIES LAWS OR (B) THE ISSUER HAS FIRST RECEIVED AN OPINION OF COUNSEL
SATISFACTORY TO IT THAT SUCH REGISTRATION, QUALIFICATION OR APPROVAL IS NOT REQUIRED.

 

UNSECURED
Convertible Promissory NOTE

(this
“Note”)

 

	$[●]	[●],
  [●], 2021

 

FOR
VALUE RECEIVED, the undersigned Provectus Biopharmaceuticals, Inc., a Delaware corporation (the “Borrower”), hereby
promises to pay to the order of [●] (the “Lender”) at the Lender’s address located at [●] or at
such other place as the Lender may designate to the Borrower in writing from time to time, the principal sum set forth in Paragraph
A below, or, if less, so much thereof as is outstanding hereunder, in lawful money of the United States of America and in immediately
available funds, and to pay interest on said principal sum or the unpaid balance thereof, in like money at said office. This Note is
issued as a part of a series of similar notes (collectively, the “Notes”) to be issued to several lenders (collectively,
the “Lenders”) as part of a single financing round (the “2021 Financing Round”) pursuant to the
Financing Term Sheet approved by the Board of Directors of the Borrower on August 13, 2021. Capitalized terms used in this Note but not
immediately defined shall have the meanings set forth in Paragraph L below.

 

A.
Principal.

 

This
Note shall have a principal amount of [●] and no/00 Dollars ($[●]).

 

B.
Interest

 

Subject
to Paragraph I, interest on this Note shall accrue on the outstanding principal amount hereof at a rate equal to eight percent
(8%) per annum, calculated on the basis of a 365-day year, commencing on the date of this Note (the “Interest Rate”).

 

    	1

     

    

 

C.
Payment Terms; Prepayment.

 

(i)
Payments on this Note shall be applied in the following order: first to accrued but unpaid interest and second to principal. If any payment
on this Note becomes due and payable on a day other than a Business Day, the payment date thereof shall be extended to the next succeeding
Business Day. Principal and interest under this Note may be pre-paid in whole or in part at any time without premium or other prepayment
charge.

 

(ii)
Within ten (10) Business Days following the initial closing of a Qualified Financing, the Lender may elect to receive payment of, and
upon such election, the Borrower shall be required to pay, all of the Outstanding Amount under this Note equal to the proceeds received
by the Borrower from a Qualified Financing before such proceeds are applied to any other purpose by the Borrower (such payments, the
“Future Financing Payments”). Any amounts received by the Lender as Future Financing Payments shall be applied in
the following order: first to accrued but unpaid interest and second to principal. Notwithstanding the foregoing, in the event more than
one Lender elects to receive Future Financings Payments in connection with the same Qualified Financing (such Lenders, the “Electing
Lenders”) and the net proceeds of such Qualified Financing are insufficient to satisfy all of the Future Financing Payments
of the Electing Lenders, the Borrower shall make such Future Financing Payments to the Electing Lenders on a pro rata basis based
upon the ratio the principal amount of each Electing Lender’s Note bears to the aggregate principal amounts of all Electing Lender’s
Notes.

 

D.
Events of Default; Remedies.

 

(i)
The Borrower shall be deemed to be in default under this Note if (each of the following events is referred to in this Note as an “Event
of Default”): (a) the Borrower fails to pay, when due, any payment of principal or interest under this Note, which continues
for a period of ten (10) days after the due date of such payment, (b) any action commenced by or against the Borrower under the Federal
Bankruptcy Code, or other statute for the relief of creditors, which is not dismissed within sixty (60) days, or (c) liquidation of the
Borrower.

 

(ii)
Upon the occurrence and during the continuance of an Event of Default, the Lender, at the Lender’s option, may (a) allow this Note
to remain outstanding and continue to accrue interest at the Interest Rate, or (b) declare the outstanding principal balance of and all
accrued but unpaid interest on this Note to be immediately due and payable.

 

E.
Use of Proceeds.

 

This
Note may be used to fund the Borrower’s discovery and drug development program as currently conducted and as modified in the future
by the Board of Directors and for general corporate and administrative expenses approved by the Board of Directors.

 

    	2

     

    

 

F.
Conversion.

 

(i)
Voluntary Conversion; Series D-1 Shares. The Lender, at the Lender’s option, may elect to convert all of the Outstanding
Amount of this Note at any time into Series D-1 Shares. If the Lender elects to effect a conversion of this Note into Series D-1 Shares,
the Lender shall: (a) deliver a copy of the fully executed notice of conversion in the form attached hereto as Exhibit A (a “Notice
of Conversion”) to the Borrower and (b) surrender or cause to be surrendered this Note with delivery of the Notice of Conversion.
On the Voluntary Conversion Date, the Borrower shall issue and deliver to the Lender confirmation of the number of Series D-1 Shares
that have been issued to the Lender upon conversion of this Note, which number of Series D-1 Shares shall be calculated by dividing the
Outstanding Amount on the Voluntary Conversion Date by the Conversion Price. The Lender shall be treated for all purposes as the record
holder of such Series D-1 Shares at 12:01 am Eastern Time on the Voluntary Conversion Date and such Series D-1 Shares shall be issued
and outstanding as of such date.

 

(1)
No Fractional Shares. No fractional Series D-1 Shares are to be issued upon the conversion of this Note, but instead of any fraction
of a Series D-1 Share which would otherwise be issuable, the fraction of such Series D-1 Share shall be rounded up to the nearest whole
share.

 

(2)
Insufficient Series D-1 Shares. Notwithstanding the foregoing, if this Note is converted under the terms hereof and the number
of authorized but unissued Series D-1 Shares are insufficient to permit the conversion of the Outstanding Amount in full, Borrower will
take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued Series D-1 Shares
to such number of shares as shall be sufficient for such purposes. Until Borrower is able to effectuate such corporate action, Series
D-1 Shares shall be issued to the Lender in an amount equal to the amount of authorized but unissued Series D-1 Shares available for
issuance, and the portion of the Outstanding Amount that remains unissued shall continue to be outstanding principal and accrued but
unpaid interest of the Note.

 

(3)
Conversion of Series D-1 Shares. Conversion of Series D-1 Shares into shares of common stock, par value $0.001 per share (“Common
Stock”), of the Borrower shall be governed by the Certificate of Designation of Preferences, Rights and Limitations of Series D-1
Convertible Preferred Stock (the “Series D-1 Certificate of Designation”). One Series D-1 Share shall be convertible into
ten (10) shares of Common Stock of the Borrower, subject to any terms, conditions, and adjustments as provided in the Series D-1
Certificate of Designation.

 

(ii)
Voluntary Conversion; Future Financings. While this Note is outstanding, if Borrower consummates a Qualified Equity Financing,
Borrower will provide Lender with written notice of such Qualified Equity Financing (the “Equity Offering Notice”),
which Equity Offering Notice shall describe, in reasonable detail, the rights, privileges, and preferences of the capital stock offered
by the Company in such Qualified Equity Financing, no later than five (5) Business Days after the initial closing in such Qualified Equity
Financing. The Lender, at the Lender’s option, may irrevocably elect to convert all of the Outstanding Amount under this Note into
the shares of capital stock being purchased by the cash investors in such Qualified Equity Financing (the “New Shares”)
by delivering a Notice of Conversion to the Borrower within ten (10) Business Days following the delivery of the Equity Offering Notice.
If the Lender elects to convert this Note in accordance with this Paragraph, the Note shall convert into that number of New Shares equal
to the Outstanding Amount divided by the price per share paid by the cash investors participating in such Qualified Equity Financing.
In connection with the conversion of this Note into New Shares, the Lender shall execute and deliver to the Company all of the transaction
documents related to the Qualified Equity Financing.

 

    	3

     

    

 

(iii)
Most Favored Nation. While this Note is outstanding, if Borrower sells or issues any convertible promissory notes or other debt
instruments (“Subsequent Debt Instruments”) in a Qualified Financing on terms that differ from this Note, Borrower
will provide the Lender with written notice of such sale or issuance (the “Debt Offering Notice”), which Debt Offering
Notice shall describe, in reasonable detail, the terms of the Subsequent Debt Instruments, no later than five (5) Business Days after
the initial closing date at which such Subsequent Debt Instruments are sold by the Company. In the event the Lender determines, in its
sole discretion, that any Subsequent Debt Instrument contains terms more favorable to the holder(s) thereof than the terms set forth
in this Note, the Lender may irrevocably elect to exchange this Note for such Subsequent Debt Instrument with an original principal amount
equal to the Outstanding Amount of this Note on the date of such exchange. The Lender shall make such irrevocable election by delivering
written notice to the Company no later than ten (10) Business Days following the delivery of the Debt Offering Notice.

 

(iv)
Termination; Limitation on Multiple Elections. This Note shall automatically terminate immediately following the earliest to occur
of: (a) the Voluntary Conversion Date; (b) the date on which the Lender converts this Note into New Shares pursuant to Paragraph F(ii);
(c) the date on which the Lender exchanges this Note for a Subsequent Debt Instrument pursuant to Paragraph F(iii); or (d) the date on
which the entire Outstanding Amount of this Note is paid or prepaid in accordance with the terms hereof. For sake of clarity, the Lender
shall not be entitled to convert or exchange less than the entire Outstanding Amount of this Note under Paragraphs F(i), (ii), and (iii),
and the Lender shall not be entitled to make an election to convert or exchange this Note under Paragraph F and an election to receive
repayment under Paragraph C(ii) with respect to the same Qualified Financing; provided, that, if the Lender is entitled to receive
repayment of only a portion of the Outstanding Amount pursuant to the last sentence of Paragraph C(ii) in connection with a Qualified
Financing, then the Lender may elect to convert or exchange the remaining portion of the Outstanding Amount, not being repaid pursuant
to Paragraph C(ii), pursuant to this Paragraph F.

 

G.
Maturity Date.

 

This
Note, including interest and principal, shall be due and payable in full (i) on such date upon which an Event of Default occurs and is
continuing, (ii) upon a Change of Control of the Borrower, or (iii) twelve months after the issue date of this Note, which is [●]
[●], 2021, the earliest of such dates being the “Maturity Date.”

 

    	4

     

    

 

H.
Cumulative Remedies; No Waiver.

 

The
Lender’s rights and remedies under this Note are cumulative and in addition to all rights and remedies provided by applicable law
from time to time. The exercise or direction to exercise by the Lender of any right or remedy shall not constitute a cure or waiver of
any default, nor invalidate any notice of default or any act done pursuant to any such notice, nor prejudice the Lender in the exercise
of any other rights or remedy. No waiver of any default shall be implied from any omission by the Lender to take action on account of
such default if such default persists or is repeated. No waiver of any default shall affect any default other than the default expressly
waived, and any such waiver shall be operative only for the time and to the extent stated. No waiver of any provision of this Note shall
be construed as a waiver of any subsequent breach of the same provision. The consent of the Lender to any act by the Borrower requiring
further consent or approval shall not be deemed to waive or render unnecessary the Lender’s consent to or approval of any subsequent
act. The Lender’s acceptance of the late performance of any obligation shall not constitute a waiver by the Lender of the right
to require prompt performance of all further obligations. The Lender’s acceptance of any performance following the sending or filing
of any notice of default shall not constitute a waiver of the Lender’s right to proceed with the exercise of remedies for any unfulfilled
obligations, and the Lender’s acceptance of any partial performance shall not constitute a waiver by the Lender of any rights relating
to the unfulfilled portion of the applicable obligation.

 

I.
No Usury.

 

Nothing
herein contained, nor any transaction related hereto, shall be construed, or so operate as to require the Borrower to pay interest
in an amount or at a rate greater than the maximum allowed by applicable law. Should any interest or other charged paid by the Borrower
result in computation or earning of interest in excess of the maximum legal rate of interest permitted under the law in effect while
said interest is being earned, then any and all of that excess shall be and is waived by the Lender, and all that excess shall be automatically
credited against and in reduction of the principal balance, and any portion of the excess that exceeds the principal balance shall be
paid by the Lender to the Borrower so that under no circumstances shall the Borrower be required to pay interest in excess of the maximum
rate allowed by applicable law.

 

J.
Jurisdiction; Waiver of Jury Trial.

 

(i)
This Note shall be governed by the internal laws of the State of TENNESSEE except to the extent
superseded by Federal law. THE BORROWER HEREBY CONSENTS TO THE EXCLUSIVE JURISDICTION OF ANY STATE OR FEDERAL COURT LOCATED IN
Knox COUNTY, Tennessee AND WAIVES ANY OBJECTION
BASED ON FORUM NON CONVENIENS WITH REGARD TO ANY ACTIONS, CLAIMS, DISPUTES OR PROCEEDINGS RELATING TO THIS NOTE, OR ANY TRANSACTION RELATING
TO OR ARISING FROM THIS NOTE, OR ENFORCEMENT AND/OR INTERPRETATION OF ANY OF THE FOREGOING. Nothing
herein shall limit the Lender’s right to bring proceedings against the Borrower in the competent courts of any other jurisdiction.

 

(ii)
THE BORROWER AND THE LENDER HEREBY KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY WAIVE THE RIGHT EITHER MAY HAVE TO A TRIAL BY JURY
IN RESPECT OF ANY LITIGATION BASED HEREON OR ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS NOTE OR ANY COURSE OF CONDUCT, COURSE OF
DEALING, STATEMENTS (WHETHER WRITTEN OR VERBAL) OR ACTIONS OF EITHER PARTY. THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE BORROWER
AND THE LENDER FOR ENTERING INTO THIS AGREEMENT.

 

    	5

     

    

 

K.
Miscellaneous.

 

(i)
TIME IS OF THE ESSENCE WITH RESPECT TO THIS NOTE.

 

(ii)
Any term of this Note may be amended or waived only with the written consent of the Company and the Requisite Lenders. Any amendment
or waiver effected in accordance with this paragraph shall be binding upon the Borrower and each Lender, regardless of whether he, she,
or it has given its written consent. Notwithstanding the foregoing, (a) if any amendment or waiver materially and adversely treats one
or more Lenders in a manner that is disproportionate to such treatment of all other Lenders solely with respect to their respective rights
as holders of the Notes, such amendment or waiver shall also require the written consent of the Lenders disproportionately treated, and
(b) no amendment or waiver of this Note shall change the principal amount outstanding without the consent of the Lender. This paragraph
of the Note may not be amended without the written consent of the Company and all Lenders.

 

(iii)
The Borrower hereby waives presentment for payment, demand, notice, protest, notice of protest and notice of dishonor.

 

(iv)
Notwithstanding anything herein to the contrary, the Lender may not institute any action to collect this Note or any other action with
respect to this Note or payment hereunder without the prior consent of the Requisite Lenders. A single Lender may be designated by the
Requisite Lenders to institute any such action on behalf of all Lenders, and Lender agrees and acknowledges that such designated Lender
shall serve as the representative of all Lenders in a single action. Such Lender shall be indemnified and held harmless from and against
any and all costs, expenses, fees, and liabilities which it may incur in connection with pursuing such action and shall have no
liability whatsoever to the other Lenders for any actions taken or omitted in good faith in connection therewith. Any Lender taking action
in contravention of this paragraph shall indemnify the Borrower, its directors, officers, and representatives for all losses,
costs, and expenses (including attorneys’ fees) incurred in connection therewith.

 

L.
Definitions.

 

The
following terms used in this Note shall have the following meanings:

 

“Affiliate”
means, with respect to any Person that directly or indirectly, through one or more intermediaries, Controls, or is controlled by, or
is under common control with, such Person.

 

“Board
of Directors” means the Board of Directors of the Borrower.

 

    	6

     

    

 

“Business
Day” means each Monday, Tuesday, Wednesday, Thursday, or Friday on which banking institutions are not authorized or
obligated by law, regulation, or executive order to close in Knoxville, Tennessee.

 

“Change
of Control” means, unless otherwise approved in writing by the PRH Group, the occurrence after the date hereof of any of (a)
an acquisition after the date hereof by an individual or legal entity or “group” (as described in Rule 13d 5(b)(1) promulgated
under the 1934 Act) of effective control (whether through legal or beneficial ownership of capital stock of the Borrower, by contract
or otherwise) of in excess of 33% of the voting securities of the Borrower (other than by means of conversion or exercise of Series D
and D-1 Shares and any other securities issued together with such Series D and D-1 Shares), (b) the Borrower merges into or consolidates
with any other Person, or any Person merges into or consolidates with the Borrower and, after giving effect to such transaction, the
stockholders of the Borrower immediately prior to such transaction own less than 66% of the aggregate voting power of the Borrower or
the successor entity of such transaction, (c) the Borrower sells or transfers all or substantially all of its assets to another Person
and the stockholders of the Borrower immediately prior to such transaction own less than 66% of the aggregate voting power of the acquiring
entity immediately after the transaction, (d) a replacement at one time or within a one year period of more than one half of the members
of the Board of Directors on the date hereof, or (e) the execution by the Borrower of an agreement to which the Borrower is a party or
by which it is bound, providing for any of the events set forth in clauses (a) through (d) above.

 

“Controls”
(including the terms “controlling”, “controlled by”, and “under common control with”) means the possession,
direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership
of voting securities, by contract or otherwise.

 

“Conversion
Price” means $2.8620.

 

“Outstanding
Amount” means (a) the outstanding principal amount of this Note, plus (b) all accrued and unpaid interest.

 

“Person”
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint
venture, sole proprietorship, unincorporated organization, governmental authority, or any other form of entity not specifically
listed herein.

 

“Qualified
Equity Financing” means a Qualified Financing in which the Borrower issues and sells shares of its capital stock at a fixed
valuation or price per share, including shares of its common stock or preferred stock.

 

“Qualified
Financing” means a transaction or series of related transactions (other than the 2021 Financing Round) with the principal purpose
of raising capital pursuant to which (i) the Company issues and sells shares of its capital stock or issues debentures, bonds, promissory
notes, or other debt securities, and (ii) the Borrower receives gross proceeds from such transaction or transactions in the aggregate
amount of $20,000,000, not counting any proceeds received or deemed to be received by the Borrower from the conversion of outstanding
convertible notes (including the Notes) or other convertible securities.

 

    	7

     

    

 

“Records”
means, to the extent related to the Intellectual Property of the Borrower, all books, correspondence, files, records, invoices and other
papers and documents in Borrower’s possession or custody, including without limitation to the extent so related, all tapes, cards,
computer runs, computer programs, and other papers and documents in possession or control of Borrower or any computer bureau from time
to time acting for Borrower, whether in physical or electronic formats.

 

“Requisite
Lenders” means the Lenders holding Notes that represent at least a majority of the outstanding principal amounts of all of
the Notes issued by the Borrower as part of the 2021 Financing Round.

 

“Series
D-1 Shares” means shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share, of the Borrower.

 

“Subsidiary”
means, with respect to any Person, any other Person of which at least a majority of the securities or ownership interests having by their
terms voting power to elect a majority of the directors, managers or other persons performing similar functions is directly or indirectly
owned or controlled by such Person or by one or more of its respective Subsidiaries.

 

“Voluntary
Conversion Date” means the date which is three (3) Business Days following the date the Notice of Conversion is delivered to
the Borrower.

 

[Signatures
contained on next page.]

 

    	8

     

    

 

	 	BORROWER:
	 	 
	 	Provectus
    Biopharmaceuticals, Inc.
	 	 	                                                     
	 	 
	 	Name:	Heather
    Raines, CPA
	 	Title:	Chief
    Financial Officer

 

    	9

     

    

 

Exhibit
A

 

Form
of Notice of Conversion

(See
Attached)

 

    	 

    	 

    

 

NOTICE
OF CONVERSION

 

The
undersigned hereby irrevocably elects to convert (the “Conversion”) $__________ principal amount of the Convertible
Note plus $_________ accrued and unpaid interest on such principal amount into Series D-1 Shares of Provectus Biopharmaceuticals, Inc.
(the “Company”) according to the conditions of the Unsecured Convertible Promissory Note dated [●], 2021, as
of the date written below. No fee will be charged to the Lender for the conversion.

 

The
undersigned represents and warrants that it understands that all offers and sales by the undersigned of the Series D-1 Shares issuable
to the undersigned upon Conversion of this Unsecured Convertible Promissory Note shall be made pursuant to registration of such securities
under the Securities Act of 1933, as amended (the “Act”), or pursuant to an exemption from registration under the Act.

 

	 	Date
    of Conversion: _______________________________
	 	Applicable
    Conversion Price: ________________________
	 	Number of Conversion Securities

                                                         to be Issued: _____________________________________

	 	 

	 	Signature:	
	 	Name:	
	 	Address:	
	 	 	 
	 	 	 

 

	ACKNOWLEDGED
    AND AGREED:	 
	 	 
	PROVECTUS
    BIOPHARMACEUTICALS, INC.	 
	 	 	 
	By:	                                   	 
	Name:	 	 
	Title:	 	 
	Date:EX-10.2

 Exhibit 10.2 

FIRST AMENDMENT TO 
 SALE
AND SERVICING AGREEMENT 
 This First Amendment to Sale and Servicing Agreement, dated as of August 16, 2021 (this
“Amendment”), is by and among Santander Drive Auto Receivables LLC, as seller (the “Seller”), and Santander Consumer USA Inc. (“SC”), as servicer (in such capacity, the “Servicer”).

 WHEREAS, Drive Auto Receivables Trust 2018-2, as issuer (the “Issuer”), the
Seller, the Servicer, and Wilmington Trust, National Association, as indenture trustee (the “Indenture Trustee”) are parties to that certain Sale and Servicing Agreement, dated as of May 23, 2018 (as amended, supplemented and
modified from time to time, the “Sale and Servicing Agreement”); 
 WHEREAS, the Seller and the Servicer desire to amend
the Sale and Servicing Agreement as set forth herein; 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties hereby agree as follows: 
 SECTION 1. Definitions. Capitalized terms used in this
Amendment and not otherwise defined herein shall have the meanings assigned thereto in the Sale and Servicing Agreement, as amended hereby. 

SECTION 2. Amendments. Effective as of August 16, 2021, the Sale and Servicing Agreement is hereby amended as follows: 

(a) Section 3.2(a) is hereby amended by deleting the phrase “(B) in connection with a settlement in the event the Receivable
becomes a Defaulted Receivable” where it appears therein and replacing it with the phrase “(B) in connection with a modification, adjustment or settlement in the event the Receivable becomes a Severely Distressed Receivable”. 

(b) The following definition of “Severely Distressed Receivable” is added to Appendix A in the appropriate alphabetical order: 

““Severely Distressed Receivable” means, as of any date of determination, a Receivable (other than a Repurchased
Receivable) (i) that is 60 or more days delinquent or, if less than 60 days delinquent, the related Obligor has experienced a hardship and, in the judgment of the Servicer in accordance with its Customary Servicing Practices, it is reasonably
foreseeable that the Obligor will be unable to pay the Principal Balance of, and accrued and unpaid interest and fees on, such Receivable in accordance with its terms, (ii) that is a Defaulted Receivable, (iii) for which the Obligor is the
subject of a bankruptcy or other insolvency proceeding, (iv) for which the related Financed Vehicle has been repossessed (or for which the Servicer has initiated repossession proceedings), (v) for which the related Financed Vehicle has been
subject to theft or suffered destruction or damage that would be determined to be beyond repair in accordance with Customary Servicing Practices or (vi) for which the maturity date is in less than six months and, in the judgment of the Servicer
in accordance with its Customary Servicing Practices, it is reasonably foreseeable that the Obligor will be unable to pay the Principal Balance of, and accrued and unpaid interest and fees on, such Receivable by the maturity date.” 

  

					
		  		  	 DRIVE 2018-2: Amendment to

Sale and Servicing Agreement

 SECTION 3. Miscellaneous. The Sale and Servicing Agreement, as amended hereby, remains in
full force and effect. Any reference to the Sale and Servicing Agreement from and after the date hereof shall be deemed to refer to the Sale and Servicing Agreement as amended hereby, unless otherwise expressly stated. This Amendment shall be valid,
binding, and enforceable against a party only when executed by an authorized individual on behalf of the party by means of (i) an electronic signature that complies with the federal Electronic Signatures in Global and National Commerce Act,
state enactments of the Uniform Electronic Transactions Act, and/or any other relevant electronic signatures law, in each case to the extent applicable; (ii) an original manual signature; or (iii) a faxed, scanned, or photocopied manual
signature. Each electronic signature or faxed, scanned, or photocopied manual signature shall for all purposes have the same validity, legal effect, and admissibility in evidence as an original manual signature. Each party hereto shall be entitled
to conclusively rely upon, and shall have no liability with respect to, any electronic signature or faxed, scanned, or photocopied manual signature of any other party and shall have no duty to investigate, confirm or otherwise verify the validity or
authenticity thereof. This Amendment may be executed in any number of counterparts, each of which shall be deemed to be an original, but such counterparts shall, together, constitute only one instrument. Notwithstanding the foregoing, with
respect to any notice provided for in this Amendment or any instrument required or permitted to be delivered hereunder, any party hereto receiving or relying upon such notice or instrument shall be entitled to request execution thereof by original
manual signature as a condition to the effectiveness thereof. This Amendment shall be governed by and construed in accordance with the internal, substantive laws of the State of New York without reference to the rules thereof relating to
conflicts of law, other than Sections 5-1401 and 5-1402 of the New York General Obligations Law, and the obligations, rights and remedies of the parties hereunder shall
be determined in accordance with such laws. 
 [Signatures follow] 

  

					
		  	2	  	 DRIVE 2018-2: Amendment to

Sale and Servicing Agreement

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their
respective officers thereunto duly authorized, as of the date first above written. 
  

			
	SANTANDER DRIVE AUTO RECEIVABLES LLC, as Seller
		
	By:	 	 /s/ Mark McCastlain

	Name:	 	Mark McCastlain
	Title:	 	Vice President
	
	SANTANDER CONSUMER USA INC., as Servicer
		
	By:	 	 /s/ Corey Henry

	Name:	 	Corey Henry
	Title:	 	Vice President

  

					
		  	S-1	  	 DRIVE 2018-2: Amendment to

Sale and Servicing Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]